Kyowa Kirin, Inc.

Kura Oncology secures $330 million from Kyowa Kirin for ziftomenib, a menin inhibitor targeting KMT2A-mutated leukemia, with plans for FDA submission in 2025. The collaboration aims to develop ziftomenib across leukemias and solid tumors, with potential milestone payments up to $1.2 billion.

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report highlights 75+ companies developing 80+ therapies, including promising candidates like GA Depot, Remibrutinib, and IMU 838. Key events include Immunic's positive Phase 3 ENSURE trial interim analysis, Roche's FDA approval for Ocrevus injectable, and Sanofi's mixed results for tolebrutinib in Phase III trials. The report covers global pipeline stages, product types, molecule types, mechanisms of action, and routes of administration.

Amgen states no association between MariTide and bone mineral density changes, affirming its promise. Phase 2 data is expected later in 2024.

Roflumilast cream 0.15% showed high efficacy in treating mild to moderate atopic dermatitis in patients aged 6 years and older, with more patients achieving a validated IGA-AD score of 0/1 and minimal application site irritation.

Amgen reports Q3 2024 financial results: total revenues up 23% to $8.5 billion, GAAP EPS increased 62% to $5.22, non-GAAP EPS up 13% to $5.58, driven by strong product sales and pipeline investments.

Global exosome market to grow at ~20% CAGR by 2030, driven by chronic disease incidence, diagnostic improvements, and personalized medicine interest. North America leads, with key players like Danaher and Thermo Fisher Scientific. Notable developments include Aruna Bio's US patent for neural exosomes and EXO Biologics' EUR 16 million Series A funding.

The World Companion Diagnostics & Liquid Biopsy Summit APAC, Nov 13-14, 2024 in Singapore, brings together experts to discuss NGS, biomarker development, and clinical trial assay advancements. The event offers networking, insights, and discussions on regulatory guidelines, market access, and novel technologies for precision medicine.

Interim real-world data supports mogamulizumab's effectiveness and tolerability for mycosis fungoides (MF) or Sézary Syndrome (SS) in routine clinical practice, with no new safety signals observed.

BioNJ's 12th C-Suite Summit, on Oct. 10, 2024, at Bridgewater Marriott, convenes life sciences executives to discuss critical issues in innovation, policy, and market access. Featuring world-class speakers, the agenda includes topics on AI, talent, and R&D in mental health. Registration is $695 for BioNJ Members, $895 for non-members, and closed to media.